
Tarsus Pharmaceuticals, Inc.
Nasdaq · Biological Products, (No Diagnostic Substances)
Company Overview
A concise company profile alongside the latest public filing activity.
Tarsus Pharmaceuticals is a biopharmaceutical company that develops treatments for eye and skin conditions, including its lotilaner-based product for Demodex blepharitis, a common eyelid condition caused by mite infestation.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Azamian Bobak R.President/CEO and Board Chair | Sell | $803K | 10,000at $80.31 | Nov 13, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable TARS activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.